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Mitochondria play an important role in myocardial tissue homeostasis; therefore, deterioration
in mitochondrial function will eventually lead to cardiomyocyte and endothelial cell death and
consequently cardiovascular dysfunction. Lithium (Li+) is an effective drug for bipolar disorder
with known cardiotoxic side effects. This study was designed to investigate the effects of Li+ on
mitochondria and cardiomyocytes isolated from the heart of Wistar rat. Results revealed that
Li+ induced a concentration- and time-dependent rise in mitochondrial ROS formation, inhibition
of respiratory complexes (II), mitochondrial membrane potential (MMP) collapse, mitochondrial
swelling, and cytochrome c release in rat heart mitochondria and also induced Caspase 3 activa-
tion through mitochondrial pathway, decline of ATP and lipid peroxidation in rat cardiomyocytes.
These results indicate that the cardiotoxic effects of Li+ were initiated from mitochondrial dys-
function and oxidative stress, which finally ends in cytochrome c release and cell death signaling
heart cardiomyocytes.
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1 INTRODUCTION
Cardiotoxicity is an adverse side effect of drugs and a potentially life-
threatening response to toxic compounds and pollutants. [1] The uti-
lization of several drugs is associated with a risk of cardiovascular
complications. [2] Lithium (Li+) is a first-line treatment for bipolar disor-
der (BD),with a narrow therapeuticwindow that is toxic to humans and
the environment. [3] Li+ is known toproduce a variety of cardiovascular
effects inmanandexperimental animals. [4] These sideeffects aremore
severe during Li+ intoxication, although they can happen at therapeu-
tic levels of the metal. These effects include bradycardia, hypotension
[5], reduced cardiac output, and cardiac arrhythmias. [6] Li+ may also
induce several electrocardiographic (ECG) changes, including dysfunc-
tion of sinus node, disturbances of atrioventricular conduction, non-
specific T-wave flattening, and reversible premature ventricular con-
tractions. However, the effect of Li+ on QT interval has not been fully
explained [7]. Animal studies havedemonstrated that Li+ depresses the
intracellular potassium (IK) concentration. Li+ also replaces calcium.
Therefore, interaction between Li+ and IK, ICa, the sodium/calcium
(Na/Ca) exchange currents and sodium/potassium (N/K) pump have
been suggested. These disturbances seem to induce the above-
mentioned ECG changes. [4,8,9] Mitochondria are intracellular com-
partments capable of Ca2+ uptake and release mainly through the
mitochondrial uniporter and the mitochondrial Ca2+/Na+ exchanger,
respectively. Therefore, mitochondria can considerably participate in
Ca2+ homoeostasis and Ca2+ signaling. [10] Mitochondria also has
an important role in myocardial tissue homeostasis; therefore, any
deterioration in mitochondrial function will eventually leads to car-
diomyocyte, myocarditis, cardiomyopathy, endothelial cell death, and
consequently cardiovascular dysfunction. [11] Mitochondrial toxicity
develops as a result of several mechanisms which interfere with
the mitochondrial respiratory chain or inhibition of the important
mitochondrial enzymes. The final phase of mitochondrial dysfunction
induces loss of mitochondrial membrane potential and an increase
in mitochondrial oxidative/nitrative stress, eventually leading to cell
death. [12] Because of the abundance of mitochondria in cardiomy-
ocytes, the role of mitochondria in calcium homeostasis and the
close relationship linking oxidative metabolism with myocardial func-
tion and viability, mitochondrial dysfunction should often be consid-
ered as a prime suspect in cardiotoxicity, especially when cardiomy-
ocyte survival is compromised. Despite the various findings indicating
the occurrence of mitochondrial dysfunction in BD [13] and other
separate evidences claiming the association of heart mitochondrial
dysfunction with Li+ consumption, toxicity of Li+ on heart mito-
chondria has not been previously investigated. We therefore decided
to evaluate the mitochondrial mechanisms involved in Li+-induced
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cardiotoxicity such as mitochondrial functionality, mitochondrial
swelling, ROS formation, collapse of mitochondrial membrane poten-
tial (MMP), cytochrome c release as an initiator of apoptosis, ADP/ATP
ratio, Caspase 3 activation and lipid peroxidation in mitochondria and
cardiomyocytes isolated from the heart of rat.
2 MATERIALS AND METHODS
2.1 Materials
Li+ carbonate and other chemicals were procured from Sigma–Aldrich
(Taufkrichen, Germany). All chemicals were of the high commercial
grade.
2.2 Animals
Male Wistar rats weighing 150–200 g with access ad libitum to water
were utilized in the experiments. The rats were kept in separate cages
under artificial light with 12 h light/dark cycle, an environmental tem-
perature of 21°C–23°C with a 50%–60% relative humidity. All exper-
iments were performed according to the ethical standards and proto-
cols approved by the Committee of Animal Experimentation of Shahid
Beheshti University of Medical Sciences, Tehran, Iran. After the ani-
malswere decapitated, their heartswere quickly extracted; the tissues
were pooled and rapidly rinsed utilizing isotonic saline buffer. These
samples were utilized for the isolation of mitochondria.
2.3 Mitochondrial assays
2.3.1 Preparation ofmitochondria
Rats were decapitated and the heart was surgically removed, minced,
and homogenizedwith a glass hand held homogenizer in ice-coldmito-
chondrial isolation medium (225 mM D-mannitol, 75 mM sucrose,
and 0.2 mM EDTA, pH 7.4). Mitochondria were prepared from
the homogenate utilizing differential centrifugation as described by
Pourahmad et al., [14]. The resulting pellet was re-suspended in Tris
buffer (50mMTris–HCl, 250mM sucrose, 20mMKCl, 2.0 mMMgCl2,
and 1.0 mM Na2HPO4, pH 7.4). The Coomassie blue protein-binding
method was used to determine the protein concentration. [15] Li+ car-
bonate was dissolved in Milli-Q water and the concentrations of Li+
were chosen based on previous study. [16] Mitochondrial suspension
was incubated with different concentrations of Li+ (75–1000 𝜇M) for
1 h before starting the experiments. Since toxicity of Li+ occurs with
serum concentrations >1.5 ± 2.0 mmol/L in humans, none of the con-
centrations used in this in vitro study was at Li+ blood toxic range. [17]
Homogenization, as well as the following steps, must be carried out
at 4°C to minimize the activation of damaging phospholipases and
proteases. [14]
2.3.2 Quantification ofmitochondrial ROS level
After incubating isolated heart mitochondria with Li+ (0, 75, 125,
250, and 500 𝜇M) in respiration buffer containing 0.32 mM sucrose,
10 mM Tris, 20 mM Mops, 50 𝜇M EGTA, 0.5 mM MgCl2, 0.1 mM
KH2PO4, and 5 mM sodium succinate, the mitochondrial H2O2 pro-
duction was assayed by F-2500 fluorescence spectrophotometer
(HITACHI) using DCFH-DA (final concentration, 10 𝜇M) for a period
of 60min. Excitation and emission wavelengths were 485 and 530 nm,
respectively. [18,19]
2.3.3 Measurement of complex II activity through
theMTT assay
The activity of mitochondrial complex II (succinate dehydrogenase)
was assayed via the measurement of MTT reduction [21]. Briefly, after
incubating mitochondrial suspensions with Li+ (0, 75, 125, 250, and
500 𝜇M) at 30°C for 60min and adding 0.4%MTT to themedium, sam-
ples were incubated at 37°C for 30 min. Then, the purple formazan
crystals were dissolved in DMSO and the absorbance was measured
at 570 nmwith an ELISA reader (Tecan, Rainbow Thermo, Austria).
2.3.4 Determination ofmitochondrial membrane
potential in isolatedmitochondria
Rhodamine 123 as cationic fluorescent dye has been utilized for the
determination of mitochondrial membrane potential. [20,22,23] Briefly,
after incubating mitochondrial suspensions with Li+ (0, 75, 125, 250,
and 500 𝜇M) at 30°C for 5 min,10 𝜇M of rhodamine123 was added
to the mitochondrial respiration buffer (220 mM sucrose, 68 mM D-
mannitol, 10 mM KCl, 5 mM KH2PO4, 2 mM MgCl2, 50 𝜇M EGTA,
5 mM sodium succinate, 10 mM HEPES, 2 𝜇M Rotenone). The fluo-
rescence wasmeasured via Schimadzou RF-5000U fluorescence spec-
trophotometer at the excitation and emission wavelength of 490 and
535 nm, respectively. Obtained data were shown as the percentage
of mitochondrial membrane potential collapse (%ΔΨm) in all treated
(test) mitochondrial groups.
2.3.5 Determination ofmitochondrial swelling in isolated
mitochondria
The mitochondrial swelling, as a result of colloidal osmotic effects of
solute flux in and out of the mitochondrial matrix, was measured by
monitoring the absorbance at 540 nm (A540) as described by Salimi
et al. [24,25] Briefly, after incubating mitochondrial suspensions with
Li+ (0, 75, 125, 250, and 500 𝜇M) at 30°C for 5 min in swelling
buffer (70 mM sucrose, 230 mM mannitol, 3 mM HEPES, 2 mM tris-
phosphate, 5 mM succinate, and 1 𝜇M of rotenone), the absorbance
was measured at 540 nm for 60 min with an ELISA reader (Tecan).
A reduction in the absorbance indicates an increase in mitochondrial
swelling.
2.3.6 Determination of cytochrome c release from
isolatedmitochondria
Mitochondria were incubated in 1.5-mL Eppendorf tubes at 37°C for
several periods. Inhibitor ofMPTpore, cyclosporineA (Cs.A) at thefinal
concentration of 5𝜇mol/L and anti-oxidant butylated hydroxyl toluene
(BHT) also at the final concentration of 5 𝜇mol/L were added 15 min
before the addition of Li+ . After the incubation, tubeswere centrifuged
at 10,000×g. The supernatant contained the cytochrome c released
from the mitochondria, and the pellet contained the mitochondrial
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fraction. The concentration of cytochrome c was determined using
theQuantikine rat/mouse Cytochrome c Immunoassay kit provided by
R and D Systems, Inc. (Minneapolis, MN). Briefly, a monoclonal anti-
body specific for rat cytochrome cwas pre-coated onto themicroplate.
Onehundredmicro liters (100𝜇L) of conjugate (containingmonoclonal
antibody specific for cytochrome c conjugated to horseradish perox-
idase) and 50 𝜇L of control and test group were added to each well
of the microplate. One microgram (1 𝜇g) of protein from each super-
natant fraction was added to the sample wells. All of the standards,
controls and test were added to two wells of the microplate. After 2 h
of incubation, the substrate solution (100 𝜇L) was added to each well
and incubated for 30 min. After 100 𝜇L of the stop solution was added
to each well; the optical density of each well was determined via the
earlier mentionedmicroplate spectrophotometer set to 450 nm. [26]
2.4 Cardiomyocyte assays
2.4.1 Cardiomyocyte isolation
Single cardiac myocytes were isolated from rat ventricles by colla-
genase digestion. Male Wistar rats (150–200 g) were anesthetized
by ketamine and the heart extracted and placed in ice-cold isolation
buffer (0.75 mM CaCl). Isolation buffer contained 20 mM sodium
N-hydroxyethylpiperazine,-N-2-ethansulphonic acid (Hepes), 130mM
NaCl, 4.5 mM KCl, 5 mMMgCl, 1 mM NaHPO, 21 mM glucose, 5 mM
Na-pyruvate, pH 7.25 with NaOH. The heart was perfused with isola-
tion buffer plus 0.75 mM CaCl2 at 37°C for 4 min before switching to
Ca2+-free buffer (isolation buffer plus 90 0mM EGTA) for 4 mm. The
perfusate was then switched to “enzyme solution” containing 50 mL
isolation buffer plus 50mg collagenase (Worthington, type I), 5mgpro-
tease (Sigma, type XIV), and 15 mM CaCl2. The enzyme solution was
continued for approximately 15 min until a soft tissue was obtained.
The heart was then washed with isolation buffer containing CaCl2
(150 mM). Ventricles were removed, minced into 10 pieces with small
scissors and shaken for 5 min at 37°C in 20–25 mL CaCl2 isolation
buffer (150mM). After filtration, cells were allowed to sediment in this
buffer for 7 min. The supernatant was removed and cells resuspended
in 0.5mMCaCl2, the processwas repeated and cellswere finally resus-
pended in medium containing DMEM (80%), M199 (20%), penicillin
(200 U/mL), streptomycin (0.2 mg/mL), and ITSS (insulin transferrin-
sodium selenite supplement, 0.5%). [27]
2.4.2 Determination of the ATP/ADP ratio in isolated
cardiomyocyte
Changes in the ATP/ADP ratio were utilized to differentiate modes of
cell death and viability. Increased levels of ATP and reduced levels of
ADP indicate proliferating cells. Conversely, reduced levels of ATP and
increased levels of ADP represent apoptotic or necrotic cells where
the reduction in ATP and increase in ADP are much more pronounced
in necrosis versus apoptosis. Briefly, isolated cardiomyocytes were
treated with various concentrations of Li+ (35, 75, 125, and 250 𝜇M)
for 180 min in a medium containing DMEM (80%), M199 (20%), peni-
cillin (200U/mL), streptomycin (0.2mg/mL), and ITSS (0.5%).Cellswere
washed with ice-cold PBS and suspended in buffer containing 25 mm
HEPES, pH 7.5, 10% sucrose, 0.1% CHAPS, 2 mm DDT, 5 mm EDTA,
1 mm PMSF, and 1 𝜇M pepstatin A. The cardiomyocytes suspension
was forced through a 25-gauge needle 10 times to crush the cells. The
homogenate was centrifuged at 4°C for 1 h at 100,000×g and then
ATP/ADP ratio was measured in homogenate with the ADP/ATP Ratio
Assay kit (MAK135 sigma).
2.4.3 Determination of Caspase 3 activation in isolated
cardiomyocyte
Isolated cardiomyocytes were treated with vehicle; Li+ (125 𝜇M),
Li+ + Z-DEVD, Li+ + Z-IETD, Li+ + BHT, and Li+ + Cs.A, in six distinct
groups for 180 min in medium containing DMEM (80%), M199 (20%),
penicillin (200 U/mL), streptomycin (0.2 mg/mL), and ITSS (0.5%). Cells
were washed with ice-cold PBS without Ca2+ andMg 2+, suspended in
buffer containing 25 mm HEPES, pH 7.5, 10% sucrose, 0.1% CHAPS,
2 mm DDT, 5 mm EDTA, 1 mm PMSF, and 1 𝜇M pepstatin A, and were
allowed to swell for 20 min on ice. The suspension was forced through
a 25-gauge needle 10 times to crush the cells. The homogenate was
centrifuged at 4°C for 1 h at 100,000×g. The Caspase 3 activation
was measured by the Caspase 3 colorimetric assay kit. The Caspase 3
colorimetric assay is based on the hydrolysis of the peptide substrate
acetyl-Asp-Glu-Val-Asp p nitroanilide (Ac-DEVD-pNA) by Caspase 3,
resulting in the release of the p-nitroaniline (pNA) moiety. pNA has a
𝜆max at 405 nm. The concentration of the pNA released from the sub-
strate was calculated from the absorbance values at 405 nm or from a
calibration curve preparedwith defined pNA solutions.
2.4.4 Determination of lipid peroxidation in isolated
cardiomyocyte
Lipid peroxidation is the degradation of lipids; it occurs due to oxida-
tive damage and is a useful marker for oxidative stress. Polyunsatu-
rated lipids are susceptible to oxidative attack, typically by reactive
oxygen species, resulting in a well-defined chain reaction with the pro-
duction of end products such as malondialdehyde (MDA). Cardiomy-
ocytes were treated with various concentrations of Li+ (75, 125, and
250 𝜇M) and Li+ + BHT for 180 min in a medium containing DMEM
(80%), M199 (20%), penicillin (200 U/mL), streptomycin (0.2 mg/mL),
and ITSS. Cardiomyocytes lipid peroxidation was determined by mea-
suring the amount of thiobarbituric acid-reactive substances (TBARS)
formed during the decomposition of lipid hydroperoxides by follow-
ing the absorbance at 532 nm in a Beckman DU
R©
-7 spectrophotome-
ter after treating 1 mL aliquots of cardiomyocyte suspension (106
cells/mL) with trichloroacetic acid (70%, w/v) and boiling the suspen-
sion with thiobarbituric acid (0.8%, w/v) for 20min.
3 RESULTS
3.1 Mitochondrial assays
3.1.1 Succinate dehydrogenase activity
Mitochondrial succinate dehydrogenase (complex II) activity was
assessed by the MTT test after 1 h incubation of isolated heart
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F IGURE 1 Effect of the Li+ on succinate dehydrogenase activity in
rat heart mitochondria. SDH activity was measured using MTT dye as
described inMaterials and Methods. Isolated mitochondria (0.5 mg/mL)
were incubated within 1 h with various concentrations of Li+ con-
centration (75,125, 250, 500, and 1000 𝜇M). Values were expressed
as mean ± SD of three separate determinations using the one-way
ANOVA test, followed by the post-hoc Tukey test. ***P < 0.001 com-
paredwith untreated control mitochondria.
mitochondria with different concentrations of Li+ (75, 125, 250, 500,
and 1000 𝜇M). As shown in Figure 1, a significant decrease in the
mitochondrial metabolism of MTT to formazan (P < 0.001) was seen
after following addition of different concentrations of Li+. As shown in
Figure 1, Li+ (500 and 1000 𝜇M) caused a significant decrease in the
enzyme activity.
3.1.2 ROS formation assay
As shown in Figure 2A, Li+ (75, 125, and 250 𝜇M) induced significant
increase at ROS (H2O2) formation in isolated heart mitochondria. As
demonstrated inFigure2A, Li+-inducedmitochondrialROSproduction
was time and concentration dependent. Amore substantial increase in
mitochondrial ROS formation was observed in higher concentrations
of Li+ (125 and 250 𝜇M).
3.1.3 MMP assay
The uptake of the cationic fluorescent dye, rhodamine 123, has been
used for the measurement of mitochondrial membrane potential col-
lapse. As shown in Figure 2B, different concentrations of Li+ (75, 125,
and 250 𝜇M) significantly decreased the MMP in a concentration and
timedependentmanner (P<0.0001).CaCl2 (100𝜇M), a known inducer
of mitochondrial permeability transition (MPT) was used as a positive
control (data not shown).
3.1.4 Mitochondrial swelling
The decreased absorbance at 540 nm (A540) was used as indicator
in mitochondrial swelling assay which is a criteria of mitochondrial
membrane permeability. Addition of different concentrations of Li+
(75, 125, and 250 𝜇M) to isolated mitochondrial suspensions leads to
mitochondrial swelling in a concentration and time-dependentmanner
(Fig. 3A).
3.1.5 Cytochrome c assay
Our results showed that Li+ is significantly caused mitochondrial
swelling and collapse of the mitochondrial membrane potential. These
events could result in mitochondrial permeability transition and
release of cytochrome c frommitochondria into the cytosolic fraction.
As shown in Figure 3B, Li+ (125 𝜇M) induced significant (P < 0.05)
release of cytochrome c on the rat heart mitochondria. Significantly,
the pretreatment of Li+-treated mitochondria with the MPT inhibitor,
Cs.A and BHT, an antioxidant, inhibited cytochrome c release com-
paredwith the sole treatment of Li+ (125 𝜇M) (P< 0.05), indicating the
role of oxidative stress andMPT pore opening in cytochrome c release.
3.2 Cardiomyocytes assessment
3.2.1 Cardiomyocyte ATP/ADP ratio
As shown in Figure 4A, Li+ in applied concentrations (35, 75, 125,
and 250 𝜇M) significantly decreased ATP/ADP ratio (P < 0.05) in rat
cardiomyocytes.
3.2.2 Caspase 3 assay
As shown in Figure 4B, Li+ (125 𝜇M) significantly increased the activ-
ity of apoptosis final mediator, caspae-3 in cardiomyocytes. To clarify
the upstreammechanism involved in Li+-inducedCaspase 3 activation,
we investigated the pretreating effect of Z-IETD a Caspase 8 inhibitor
and Cs.A, anMPT pore sealing agent and BHT, a ROS scavenger on Li+-
treated cardiomyocytes. Our results showed that only Cs.A and BHT
but notZ-IETDpreventedLi+-inducedCaspase3activation (P<0.001)
suggesting that Li+ activates a ROS-mediated mitochondrial intrinsic
pathway in cardiomyocyte which could end in apoptosis.
3.2.3 Lipid peroxidation
As shown in Figure 5, a significant amount of TBARS was formed after
addition of Li+ (75, 125, and 250 𝜇M) into rat cardiomyocytes. The
TBARS concentrations markedly increased by Li+ (P < 0.05) in rat
cardiomyocytes at 3 h following incubation in cardiomyocytes. Li+-
induced TBARS was prevented by ROS scavenger (BHT), MPT pore-
sealing agents (Cs.A).
4 DISCUSSION
Toxicity of Li+ which diagnosed with serum concentrations >1.5 ±
2.0 mmol/L, occasionally occurs at therapeutic levels in adults
(usually in the elderly). [17] Concentrations higher than 3.5 mmol/L
are potentially fatal and hemodialysis is the only recommended
therapeutic solution. [28] Signs and symptoms for Li+ overdose also
includes cardiac dysrhythmias and acute renal failure. [29] Although
the cardiotoxicity effects of Li+ has recently been recognized, the
cellular mechanisms of its cardiotoxicity is poorly understood. [5] The
findings obtained from this study revealed that Li+ has toxic effect
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F IGURE 2 Effect of Li+ in heart mitochondria on ROS formation (A) and MMP (B). ROS formation was evaluated after addition of Li+ concen-
tration (75, 125, and 250 𝜇M) after 60 min incubation. ROS formation was determined by flourimetry using DCF-DA as described in Materials
and Methods. The values are expressed as means ± SD (n = 3). ****P < 0.0001; compared with untreated control mitochondria using the two-way
ANOVA test, followed by the post-hoc bonferroni test (A).
Mitochondrial membrane potential collapse (∆Ψ%) was measured by Rhodamine 123 as described in Materials and Methods. The effect of Li+
concentration (75, 125, and 250 𝜇M) on the mitochondrial membrane potential decrease in heart mitochondria was evaluated. The values are
expressed as means ± SD (n = 3). ****P < 0.0001; compared with untreated control mitochondria using the two-way ANOVA test, followed by the
post-hoc bonferroni test (B).
F IGURE 3 Effect of Li+ on rat heart mitochondrial swelling (A) and cytochrome c release (B). Mitochondrial swelling was measured by determi-
nation of absorbance at 540 nm as described inMaterials andMethods after addition of different concentrations of Li+ (75, 125, 250, and 500 𝜇M).
Values represented as mean± SD (n= 3). ****P< 0.0001 comparedwith untreated control mitochondria using the two-way ANOVA test, followed
by the post-hoc bonferroni test (A).
As shown in graph B Li+ (125 𝜇M) induced cytochrome c release from isolatedmitochondria and also pretreatmentwith BHT andCs.A significantly
inhibited cytochrome c release from mitochondria. The amount of expelled cytochrome c from mitochondrial fraction into the suspension buffer
was determined using human Cytochrome c ELISA kit as described above. Values were expressed as mean ± SD of three separate determinations
using the one-way ANOVA test, followed by the post-hoc Tukey test (B).
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F IGURE 4 Li+ -induced ATP decreasing in isolated cardiomyocytes (A) and Caspase 3 activity (B). ADP/ATP ratio was determined by Luciferin
/Luciferase Enzyme System as described in Materials and Methods. Values are presented as mean ± SD (n = 3) using the one-way ANOVA test,
followed by the post-hoc Tukey test. *: Significant difference in comparison with untreated control (P < 0.05). Rat cardiomyocyte (106 Cells/mL)
were incubated in conventional condition (37°Cand5%CO2-air) following the addition of Li
+ . Caspase3 activitywas determinedby Sigma–Aldrich
kit. The kit determines produced pNA that is released from the interaction of Caspase 3 andAC-DEVD-pNA (peptide substrate). As shown in graph
B, Li+ (125 𝜇M) significantly increased the activity of caspae-3 in cardiomyocytes. However only Cs.A (5 𝜇M) and BHT (5 𝜇M) but not Z-IETD
(10 𝜇M) prevented Li+-induced Caspase 3 activation. Values are expressed as mean± SD of three separate experiments (n = 3) using the one-way
ANOVA test, followed by the post-hoc Tukey test. ***: Significant difference in comparison with untreated control and Li+ treated (P< 0.001).
F IGURE 5 Rat cardiomyocytes (106 cells/mL) were incubated in at 37°C for 3 h following the addition of Li+ (125 𝜇M). TBARS formation was
expressed as nMconcentrations. Values are expressed asmean±SDof three separate experiments (n=3) using theone-wayANOVAtest, followed
by the post-hoc Tukey test. ***: Significant difference in comparison with untreated control cardiomyocyte (P < 0.001). ###: Significant difference
in comparison with Li+-treated cardiomyocyte (125 𝜇M) and preventive agent (BHT) (P< 0.001).
on heart mitochondria and inhibit the activity of succinate dehydro-
genase as functionality biomarker in mitochondria. Li+ also reduced
ATP in isolated cardiomyocytes (Fig. 4). Many drugs may directly
or indirectly induce oxidative stress through the mitochondria via
redox cycling or promoting iron accumulation and oxidative/nitrative
modifications of mitochondrial proteins. This may play a crucial role
in the development of myocardial dysfunction. [30] Oxidative/nitrative
modification may trigger potentially harmful events, including
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dissociation of catalytic subunits of enzymes, local or global unfolding,
aggregation, or fragmentation, all promoting degradation of modified
proteins leading to autophagy/mitophagy and endoplasmic reticulum
stress. [31] The results obtained from this study demonstrate that Li+
raises the formation of ROS in heart mitochondria. Increased ROS
formation in cardiomyocytes may induce the activation of apoptotic
and necrotic cell death. [32] The results obtained from this study also
revealed that Li+ activates Caspase 3 and this activation is dependent
onmitochondrial pathway (Fig. 4).
Mitochondria-induced oxidative stress and the increase in mito-
chondrial and intracellular Ca2+ favor each other in a vicious relation-
ship that amplifies damaging processes. [33] An increased availability
of Ca2+ within mitochondria is likely to increase the accumulation of
ROS bymeans of the processes such as increased delivery of electrons
to the ETC by activating several matrix dehydrogenases [34], reduced
removal ofH2O2 resulting fromadecrease inmitochondrial content of
reduced glutathione (GSH) as a result of the inhibition of glutathione
reductase [33], direct ETC inhibition at the level of Complex I [35];
increased formation of NO resulting in reduced activity of cytochrome
oxidase [36]; binding to cardiolipin that might cause the detachment
of cytochrome c from the IMM, thus impeding electron flow between
Complex II and IV [37]; andfinallyPTPopening. [38] The results obtained
from this study confirmed the fact that Li+ induced increase in ROS
and MPT pore opening (Figs. 2 and 3). Bioenergetic failure, enzyme
inhibitions, induction of membrane disorders, the initiation of oxida-
tive stress, as well as lipid peroxidations are being attributed to the
cardiotoxic agents in mitochondria. According to our results, Li+ also
induced significant lipid peroxidation (Fig. 5).
Increased ROS generation in cardiomyocytes may trigger the acti-
vation of several mitochondrial-dependent and -independent cell
death pathways involved in both apoptotic and necrotic cell death
for example activation of caspases and poly(ADP-ribose) polymerases
(PARP)]. [39] Oxygen radical in the mitochondria may react with nitric
oxide to generate a highly reactive oxidant, peroxynitrite [32,40], which
may impair cellular function and lead to cell death [41] and/or dys-
function [42] Finally, the results obtained from this study indicate that
Li+ increases ROS formation in isolated rat heart mitochondria and
thus leads tomitochondrial dysfunction which ends in cardiomyocytes
apoptosis. Results of this study propose that nutritional consumption
of antioxidant agents could reduce cardiotoxicity effects of Li+.
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